21.3: Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.

Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the stomach. This production relies on a complex enzymatic process involving carbonic anhydrase, breaking carbonic acid into hydrogen and bicarbonate ions. Hydrogen ions are actively pumped into the gastric lumen, in exchange for potassium ions by the H⁺/K⁺ATPase pump. Although chloride ions passively follow this process, they are not part of direct exchange in the proton pump. Hydrogen and chloride ions then combine within the luminal space to form hydrochloric acid.

At the heart of acid secretion are proton pumps in the parietal cell's secretory canaliculi. These pumps play a pivotal role in the final step of acid production, exchanging luminal potassium ions with cellular hydrogen ions. This exchange creates hydrochloric acid in the gastric lumen, contributing to the acidic environment necessary for digestion.

Proton pump inhibitors inhibit these proton pumps, which is an essential step in managing peptic ulcers. Administered as enteric-coated tablets or delayed-release capsules, they dissolve in the alkaline pH of the small intestine. These inhibitors function as prodrugs, traveling through the bloodstream to accumulate in the acidic canaliculi of parietal cells.

Once inside the acidic environment, the prodrug transforms into its active form, trapped within the canaliculi. The activated drug irreversibly binds with sulfhydryl groups, inactivating the proton pumps. This binding disrupts the transport of hydrogen ions, effectively suppressing gastric acid secretion.

Understanding the complex processes behind gastric acid secretion and the targeted action of proton pump inhibitors provides valuable insights into managing peptic ulcers. By disrupting the final step in the acid-secretory pathway, these inhibitors offer a crucial defense against the erosive effects of excess gastric acid, promoting the healing of peptic ulcers and restoring the delicate balance within the stomach.

Two of the main contributors to peptic ulcer formation are H. pylori infections or NSAID use, both facilitating gastric acid production.

Gastric acid is secreted by proton pumps located in the parietal cell.

The HCO₃^_ ions inside the cell exchanges for Cl^- ions, which, along with K⁺ ions, enter the gastric lumen.

The proton pumps exchange the luminal K⁺ ions with the cellular H⁺ ions. These ions combine to produce HCl acid.

These pumps can be inhibited by proton pump inhibitors, decreasing gastric acid secretion.

These inhibitors are administered as enteric-coated tablets or delayed-release capsules that dissolve in alkaline pH.

The prodrug travels through the bloodstream and accumulates in the acidic canaliculi, converting to its active form.

The activated drug binds irreversibly with the sulfhydryl group, inactivating the pump. It blocks H⁺ ions transport and suppresses gastric acid secretion.